Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRENT M BOYCE

Allopathic & Osteopathic Physicians Dermatology

NPI
1417944786
CMS profile
199891
Location
SEBEWAING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$37,612.48

183 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRENT M BOYCE

NPI 1417944786 · CMS profile ID 199891

Allopathic & Osteopathic Physicians / Dermatology

SEBEWAING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417944786?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRENT M BOYCE, NPI 1417944786, CMS profile ID 199891. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417944786?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRENT M BOYCE, NPI 1417944786, CMS profile ID 199891. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417944786?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRENT M BOYCE, NPI 1417944786, CMS profile ID 199891, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417944786?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

183 matching records · $37,612.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 183 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–183 of 183.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $20.2203/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731295707 CMS
Janssen Biotech, Inc. $4.2503/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341409 CMS
AbbVie, Inc. $20.3803/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916197 CMS
AbbVie, Inc. $100.0003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916191 CMS
Amgen Inc. $19.2603/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731295705 CMS
Janssen Biotech, Inc. $4.0503/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341405 CMS
Novartis Pharmaceuticals Corporation $20.2603/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658863127 CMS
AbbVie, Inc. $1,200.0003/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916187 CMS
AbbVie, Inc. $1,200.0003/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916189 CMS
AbbVie, Inc. $10.3803/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916193 CMS
Novartis Pharmaceuticals Corporation $3.6302/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658863123 CMS
Sun Pharmaceutical Industries Inc. $3.7402/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704609419 CMS
Celgene Corporation $23.7902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673001169 CMS
AbbVie, Inc. $18.7002/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916195 CMS
Amgen Inc. $22.4802/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731295703 CMS
UCB, Inc. $16.8302/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688257177 CMS
Novartis Pharmaceuticals Corporation $12.9802/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658863163 CMS
PFIZER INC. $14.2702/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671891859 CMS
AbbVie, Inc. $9.3302/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916185 CMS
Celgene Corporation $17.8301/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672722617 CMS
GENZYME CORPORATION $18.8301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694271195 CMS
Galderma Laboratories, L.P. $11.4501/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687665975 CMS
Janssen Biotech, Inc. $6.7801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341397 CMS
Janssen Biotech, Inc. $1.6901/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341377 CMS
Janssen Biotech, Inc. $12.5801/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341381 CMS
Janssen Biotech, Inc. $1.1201/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341385 CMS
Sun Pharmaceutical Industries Inc. $2.9201/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704609417 CMS
Janssen Scientific Affairs, LLC $55.7801/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657589029 CMS
Lilly USA, LLC $16.3101/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657702343 CMS
AbbVie, Inc. $3.4701/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647916183 CMS
Amgen Inc. $19.5101/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731295701 CMS
Janssen Biotech, Inc. $3.0001/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658341371 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.2001/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684569459 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37,612.48 183
PY2020 $12,590.65 109
PY2021 $9,161.98 192
PY2022 $29,533.99 256
PY2023 $39,271.93 250
PY2024 $32,037.58 254
PY2025 $10,852.54 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $170,614.83 30
PY2024 Recipient $114.46 1
PY2024 Principal investigator $274,889.87 48
PY2023 Principal investigator $150,721.14 105
PY2022 Principal investigator $139,588.98 73
PY2021 Principal investigator $266,878.68 83
PY2020 Recipient $884.40 2
PY2020 Principal investigator $411,810.28 128
PY2019 Recipient $22,443.33 2
PY2019 Principal investigator $657,648.35 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $884.34 12/31/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202533875
Principal investigator 1 ABBVIE INC. $1,500.00 12/24/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202532024
Principal investigator 1 ABBVIE INC. $650.00 12/24/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202532036
Principal investigator 1 Amgen Inc. $5,150.00 12/24/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246641961
Principal investigator 1 ABBVIE INC. $2,500.00 10/23/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (Sleep Up) No dispute reported 06/30/2026 1202518313
Principal investigator 1 Eli Lilly and Company $18,835.00 08/18/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187882532
Principal investigator 1 Eli Lilly and Company $2,952.36 07/17/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187882534
Principal investigator 1 ABBVIE INC. $4,500.00 06/12/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202491107
Principal investigator 1 ABBVIE INC. $5,100.00 06/03/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202487805
Principal investigator 1 Eli Lilly and Company $14,000.00 06/02/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187879805
Principal investigator 1 PFIZER INC. $15,843.00 05/30/2025 Non-covered Recipient Entity
Great Lakes Research Group Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228773625
Principal investigator 1 ABBVIE INC. $5,700.00 05/29/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202486975
Principal investigator 1 ABBVIE INC. $390.00 05/29/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202486977
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,751.00 05/23/2025 Non-covered Recipient Entity
Great Lakes Research Group
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235997059
Principal investigator 1 Amgen Inc. $14.75 03/25/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC- SHEFFIELD
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246641957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.75 03/03/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,542.00 03/03/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 03/03/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,114.00 03/03/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156440
Principal investigator 1 Eli Lilly and Company $1,163.99 02/10/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187881010
Principal investigator 1 ABBVIE INC. $3,600.00 02/06/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202446824
Principal investigator 1 ABBVIE INC. $19,400.00 02/06/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202446828
Principal investigator 1 ABBVIE INC. $2,000.00 02/05/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202443977
Principal investigator 1 ABBVIE INC. $1,500.00 02/05/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202443998
Principal investigator 1 ABBVIE INC. $300.00 02/05/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202444007
Principal investigator 1 ABBVIE INC. $1,633.31 02/05/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202444015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/24/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149522
Principal investigator 1 Eli Lilly and Company $10,448.00 01/17/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187882050
Principal investigator 1 Eli Lilly and Company $6,200.00 01/17/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187882052
Principal investigator 1 Eli Lilly and Company $33,140.58 01/07/2025 Non-covered Recipient Entity
GREAT LAKES RESEARCH GROUP INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187882830